Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Autor:
Carol Cronenberger, Sarah Hackley, Hideto Kameda, Sebastião Cezar Radominski, Muhammad I. Rehman, Rieke Alten, Michael L. Tee, Alan Kivitz, Stanley Cohen, Oliver von Richter, Min Zhang
Publikováno v:
Biodrugs
Objective Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78 weeks
Autor:
Igor Bondarenko, Maciej Bryl, Kazuo Kasahara, Vladimir Ivanovich Vladimirov, Manuela Zereu, Kostas N. Syrigos, Niels Reinmuth, Angel H. Bair, Fiona Hilton, K. F. Liau
Publikováno v:
Biodrugs
Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-lin
Autor:
Alfredo Berrocal Kasay, Thomas Linde, Piotr Wiland, Elia Chalouhi El-Khouri, Sang Joon Lee, Pavel Shesternya, Francisco Fidenci Cons Molina, Janusz Jaworski, Ihor Hospodarskyy, Paweł Hrycaj, Jose Chavez-Corrales, Mauricio Abello-Banfi, Marek Brzosko, Sergii Shevchuk, Seung Cheol Shim, Dae Hyun Yoo, Armando Calvo, D. Andersone, Sławomir Jeka, Chang-Hee Suh, Sung Young Lee, Francisco G. Medina-Rodriguez, Pedro Miranda, Marek Krogulec, Won Park, Mariusz Piotrowski
Publikováno v:
Biodrugs
Objective The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and the EU (US-RTX and EU-RTX) in rheumatoid art
Autor:
Nikolas J. Onufrak, Kevin L. Winthrop, David E. Griffith, Jakko van Ingen, Dayton W. Yuen, Christopher M. Rubino, Kevin C. Mange, Sujata M. Bhavnani
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokine
Publikováno v:
Drug Safety
Introduction Valbenazine is a novel vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. Objective Using data from double-blind, placebo-controlled trials, analyses were conducted to evaluate the car
Autor:
Mohammad Ali Broumand, Yaser Jenab, Farzad Darabi, Hossein Khalili, Mojtaba Salarifar, Azita Hajhossein Talasaz
Publikováno v:
Drugs in R&D
Background and Aims Ischemia following acute myocardial infarction (AMI) increases the level of pro-fibrotic and inflammatory cytokines, including transforming growth factor (TGF)-β and tumor necrosis factor (TNF)-α. N-acetylcysteine (NAC) has ther